Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2386732 | 0.98 | HTR2A (0.42) | HTR2AKDM1ASIGMAR1 | |
| SCHEMBL2389607 | 0.80 | HTR2A (0.43) | HTR2AKDM1A | |
| SCHEMBL9053415 | 0.79 | HTR2A (0.41) | HTR2AKDM1ASIGMAR1 | |
| SCHEMBL2389053 | 0.79 | KDM1A (0.43) | HTR2AKDM1A | |
| Hydrochloric Acid SCHEMBL2388440 | 0.79 | HTR2A (0.42) | HTR2AKDM1ASIGMAR1 | |
| Hydrochloric Acid SCHEMBL2386915 | 0.78 | KDM1A (0.42) | HTR2AKDM1A | |
| SCHEMBL2354334 | 0.77 | HTR2A (0.42) | HTR2AKDM1ASIGMAR1 | |
| Hydrochloric Acid SCHEMBL2389677 | 0.76 | HTR2A (0.47) | HTR2AKDM1A | |
| Hydrochloric Acid SCHEMBL2388795 | 0.76 | HTR2A (0.47) | HTR2AKDM1A | |
| Hydrochloric Acid SCHEMBL2389681 | 0.76 | HTR2A (0.47) | HTR2AKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2042480-B1 | AMINOINDAN DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2013-05-01 | — | — | EP | claimed |
| US-8013018-B2 | Aminoindane derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-09-06 | — | — | US | claimed |
| US-20090186916-A1 | AMINOINDANE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-07-23 | — | — | US | claimed |
| EP-2042480-A1 | AMINOINDAN DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2009-04-01 | — | — | EP | claimed |
| CN-114728884-A | Process for the preparation of (R) -4-aminoindanes and corresponding amides | FMC农产品国际有限公司 | 2022-07-08 | — | — | CN | disclosed |
| EP-2042480-B1 | AMINOINDAN DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2013-05-01 | — | — | EP | disclosed |
| US-8013018-B2 | Aminoindane derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-09-06 | — | — | US | disclosed |
| US-20090186916-A1 | AMINOINDANE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-07-23 | — | — | US | disclosed |
| EP-2042480-A1 | AMINOINDAN DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2009-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186916-A1 | AMINOINDANE DERIVATIVE OR SALT THEREOF | GRIN3A, OPRL1, GRIN2A | HTR2A 86/4885KDM1A 3209/4885SIGMAR1 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.